MoonLake Immunotherapeuti... (MLTX)
NASDAQ: MLTX
· Real-Time Price · USD
42.92
-1.29 (-2.92%)
At close: Jun 16, 2025, 3:59 PM
44.08
2.70%
After-hours: Jun 16, 2025, 06:42 PM EDT
Company Description
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies.
It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation.
The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis.
MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
MoonLake Immunotherapeutics
| Country | CH |
| IPO Date | Oct 20, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 100 |
| CEO | Dr. Jorge Santos da Silva Ph.D. |
Contact Details
Address: Dorfstrasse 29 Zug, CH | |
| Website | https://www.moonlaketx.com |
Stock Details
| Ticker Symbol | MLTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001821586 |
| CUSIP Number | 61559X104 |
| ISIN Number | KY61559X1045 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jorge Santos da Silva Ph.D. | Co-Founder, Chief Executive Officer & Director |
| Matthias Bodenstedt | Chief Financial Officer |
| Carla Bretes | Director of Investor Relations & External Communications |
| Dr. Kristian Reich M.D., Ph.D. | Co-Founder & Chief Scientific Officer |
| Joana Cortez | Senior Director Legal & Compliance |
| Luciana Marques | Director of HR, People & Culture |
| Nicolas Mosimann Ph.D. | General Counsel |
| Nuala Brennan | Chief Clinical Development Officer |
| Oliver Daltrop Ph.D. | Chief Operations Officer |
| Tino Anthamatten | Vice President of Marketing, Market Access & Pricing |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 09, 2025 | 4 | Filing |
| Jun 09, 2025 | 4 | Filing |
| Jun 09, 2025 | 4 | Filing |
| Jun 09, 2025 | 4 | Filing |
| Jun 09, 2025 | 4 | Filing |
| Jun 09, 2025 | 4 | Filing |
| Jun 06, 2025 | 8-K | Current Report |
| May 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| May 12, 2025 | 10-Q | Quarterly Report |
| May 12, 2025 | 8-K | Current Report |